Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced that it will present on its lead vaccine
candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s
COVID-19, influenza and respiratory syncytial virus (RSV) vaccines.
The presentations are part of the 2020 World Vaccine Congress
Washington, taking place virtually September 28-October1, 2020.
Gregory Glenn, M.D, President of Research &
Development, and Vivek Shinde, M.D., Vice President, Clinical
Development, will join global public health, epidemiology,
regulatory and industry leaders to share expertise and the latest
research related to the SARS-CoV-2 virus and vaccine development to
address global health.
||Recombinant nanoparticle COVID-19 vaccine: Platform technology
for EID (Emerging Infectious Diseases)
||2:35 p.m. ET
||Dr. Gregory Glenn
||Phase 3 and beyond: Maternal RSV & older adult influenza
||8:30 am ET
||Dr. Gregory Glenn
||New Phase 3 NanoFlu data (features new Cell-mediated Immunity
||4:50 pm ET
||Dr. Vivek Shinde
For more information on the congress or to register, please
NVX-CoV2373NVX-CoV2373 is a vaccine candidate
engineered from the genetic sequence of SARS-CoV-2, the virus that
causes COVID-19 disease. NVX-CoV2373 was created using Novavax’
recombinant nanoparticle technology to generate antigen derived
from the coronavirus spike (S) protein and contains Novavax’
patented saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 contains purified protein antigens and cannot
replicate, nor can it cause COVID-19. In preclinical trials,
NVX-CoV2373 demonstrated indication of antibodies that block
binding of spike protein to receptors targeted by the virus, a
critical aspect for effective vaccine protection. In its the Phase
1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was
generally well-tolerated and elicited robust antibody responses
numerically superior to that seen in human convalescent sera.
NVX-CoV2373 is also being evaluated in a Phase 3 trial in the UK
and two ongoing Phase 2 studies, which began in August; a Phase 2b
trial in South Africa, and a Phase 1/2 continuation in the U.S. and
Australia. Novavax has secured $2 billion in funding for its global
coronavirus vaccine program, including up to $388 million in
funding from the Coalition for Epidemic Preparedness Innovations
About ResVaxResVax is an RSV
fusion (F) protein recombinant nanoparticle vaccine with aluminum
phosphate as an adjuvant. It is being developed to protect infants
from RSV disease via maternal immunization, which may offer the
best method of protection from RSV disease in infants through the
first months of life. ResVax is being evaluated in Prepare™, a
global Phase 3 clinical trial in 4,636 pregnant women, at least
3,000 of whom received the vaccine, and their infants. Prepare is
supported by an $89.1 million grant from the Bill
& Melinda Gates Foundation (BMGF).
NanoFlu™NanoFlu is a recombinant
hemagglutinin (HA) protein nanoparticle influenza vaccine produced
by Novavax in its SF9 insect cell baculovirus system.
NanoFlu uses HA amino acid protein sequences that are the same as
the recommended wild-type circulating virus HA sequences. NanoFlu
contains Novavax’ patented saponin-based MatrixM adjuvant.
About NovavaxNovavax, Inc.
(Nasdaq:NVAX) is a late-stage biotechnology company that promotes
improved health globally through the discovery, development, and
commercialization of innovative vaccines to prevent serious
infectious diseases. Novavax is undergoing clinical trials for
NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus
that causes COVID-19. NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, met all primary objectives in its pivotal
Phase 3 clinical trial in older adults. Both vaccine candidates
incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant
in order to enhance the immune response and stimulate high levels
of neutralizing antibodies. Novavax is a leading innovator of
recombinant vaccines; its proprietary recombinant technology
platform combines the power and speed of genetic engineering to
efficiently produce highly immunogenic nanoparticles in order to
address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Taylor and Erika Trahanir@novavax.com240-268-2022
Historical Stock Chart
From Oct 2020 to Nov 2020
Historical Stock Chart
From Nov 2019 to Nov 2020